Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hidehiro Takei

Showing results (111-120 of 116) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 116 results.
Digestive Diseases and Sciences|May 5, 2025
Impact of Interstitial Cells of Cajal Density and Other Factors on Clinical Outcomes Following G-POEM in Gastroparesis PatientsMaryam Mubashir, Daniyal Raza, Michelle Neice, et al.
Journal of Translational Medicine|June 22, 2019
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinomaYui Hirata-Nozaki, Takayuki Ohkuri, Kenzo Ohara, et al.
Oncology Letters|April 12, 2021
The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancerSatoshi Okazaki, Takaaki Sasaki, Shunsuke Yasuda, et al.
The Journal of Pathology. Clinical Research|March 22, 2021
Clinicopathological characteristics of Epstein-Barr virus and microsatellite instability subtypes of early gastric neoplasms classified by the Japanese and the World Health Organization criteriaHiroki Tanabe, Yusuke Mizukami, Hidehiro Takei, et al.
Cancer Immunology, Immunotherapy : CII|March 29, 2017
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapyToshihiro Nagato, Takayuki Ohkuri, Kenzo Ohara, et al.
International Journal of Clinical Oncology|November 11, 2024
Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resectionMasayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, et al.
Pageof 12

Showing results (111-120 of 116) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 116 results.
Digestive Diseases and Sciences|May 5, 2025
Impact of Interstitial Cells of Cajal Density and Other Factors on Clinical Outcomes Following G-POEM in Gastroparesis PatientsMaryam Mubashir, Daniyal Raza, Michelle Neice, et al.
Journal of Translational Medicine|June 22, 2019
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinomaYui Hirata-Nozaki, Takayuki Ohkuri, Kenzo Ohara, et al.
Oncology Letters|April 12, 2021
The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancerSatoshi Okazaki, Takaaki Sasaki, Shunsuke Yasuda, et al.
The Journal of Pathology. Clinical Research|March 22, 2021
Clinicopathological characteristics of Epstein-Barr virus and microsatellite instability subtypes of early gastric neoplasms classified by the Japanese and the World Health Organization criteriaHiroki Tanabe, Yusuke Mizukami, Hidehiro Takei, et al.
Cancer Immunology, Immunotherapy : CII|March 29, 2017
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapyToshihiro Nagato, Takayuki Ohkuri, Kenzo Ohara, et al.
International Journal of Clinical Oncology|November 11, 2024
Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resectionMasayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, et al.
Pageof 12